SCIENCE CHINA Life Sciences, Volume 60 , Issue 12 : 1399-1402(2017) https://doi.org/10.1007/s11427-017-9189-3

Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses

More info
  • ReceivedJul 9, 2017
  • AcceptedSep 16, 2017
  • PublishedNov 10, 2017


There is no abstract available for this article.

Funded by

China Natural Science Foundation(81290341,31621061 to Zheng-Li Shi)

Strategic Priority Research Program of the Chinese Academy of Sciences(XDPB0301 to Zheng-Li Shi)

National Institute of Allergy and Infectious Diseases of NIH grant(R01AI110964 to Zheng-Li Shi)

National Key Research and Development Program of China(2016YFC1201000 to Shibo Jiang)

NIH grant(R01AI098775 to Shibo Jiang,Lanying Du)


This work was supported by the National Natural Science Foundation of China (81290341, 31621061 to Zheng-Li Shi), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDPB0301 to Zheng-Li Shi), National Institute of Allergy and Infectious Diseases of National Institutes of Health grant (R01AI110964 to Zheng-Li Shi), the National Key Research and Development Program of China (2016YFC1201000 to Shibo Jiang) and NIH grant (R01AI098775 to Shibo Jiang and Lanying Du).

Interest statement

The author(s) declare that they have no conflict of interest.



Figure S1 Alignment of the RBDs of SARS-CoV Tor2 strain and bat SL-CoV strains WIV1, SHC014, and Rp3.

Figure S2 Neutralization activity of anti-SARS-CoV RBD antibodies against infection of pseudotyped SARS-CoV.

Figure S3 Plaque neutralization of SL-CoV WIV1 and SHC014 strains by anti-SARS-CoV RBD sera.

The supporting information is available online at http://life.scichina.com and https://link.springer.com. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.


[1] He Y., Lu H., Siddiqui P., Zhou Y., Jiang S.. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol, 2005, 174: 4908-4915 CrossRef Google Scholar

[2] Hu B., Ge X., Wang L.F., Shi Z.. Bat origin of human coronaviruses. Virol J, 2015, 12: 221 CrossRef PubMed Google Scholar

[3] Jiang S., He Y., Liu S.. SARS vaccine development. Emerg Infect Dis, 2005, 11: 1016-1020 CrossRef Google Scholar

[4] Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M.. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426: 450-454 CrossRef PubMed Google Scholar

[5] Wong S.K., Li W., Moore M.J., Choe H., Farzan M.. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem, 2004, 279: 3197-3201 CrossRef PubMed Google Scholar

[6] Zeng L.P., Gao Y.T., Ge X.Y., Zhang Q., Peng C., Yang X.L., Tan B., Chen J., Chmura A.A., Daszak P., Shi Z.L.. Bat severe acute respiratory syndrome-like coronavirus WIV1 encodes an extra accessory protein, ORFX, involved in modulation of the host immune response. J Virol, 2016, 90: 6573-6582 CrossRef PubMed Google Scholar

[7] Zhou P., Han Z., Wang L.F., Shi Z.. Identification of immunogenic determinants of the spike protein of SARS-like coronavirus. Virol Sin, 2013, 28: 92-96 CrossRef PubMed Google Scholar

[8] Zhu Z., Chakraborti S., He Y., Roberts A., Sheahan T., Xiao X., Hensley L.E., Prabakaran P., Rockx B., Sidorov I.A., Corti D., Vogel L., Feng Y., Kim J.O., Wang L.F., Baric R., Lanzavecchia A., Curtis K.M., Nabel G.J., Subbarao K., Jiang S., Dimitrov D.S.. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA, 2007, 104: 12123-12128 CrossRef PubMed ADS Google Scholar

  • Figure 1

    Cross-neutralization activity of anti-SARS-CoV RBD antibodies against infection of bat SL-CoV strain WIV1 and SHC014. The mAbs (A) and mouse sera (pAbs) (B) were diluted as indicated in the figure. The neutralization activities were measured by plaque reduction neutralization assay. NC, negative control.


Contact and support